Table 2.
Correlation of FR+CTCs levels and clinical characteristics in prostate cancer.
| Characteristics | No. of patients | FR+CTC(FU/3 ml, means ± standard error) | p |
|---|---|---|---|
| Prostate cancer | 30 | ||
| Age | p = 0.257 | ||
| ≤65 | 16 (53.3%) | 10.36 ± 1.10 | |
| >65 | 14 (46.7%) | 12.94 ± 1.93 | |
| Tumor stage | p = 0.579 | ||
| T2 | 14 (46.7%) | 11.043 ± 1.1.5 | |
| T3 | 16 (53.3%) | 12.35 ± 1.73 | |
| Gleason grading | p = 0.276 | ||
| 1/2 | 12 (40.0%) | 10.20 ± 1.70 | |
| 3/4/5 | 18 (60.0%) | 12.76 ± 1.56 | |
| Prognostic grading | p = 0.452 | ||
| 1/2b | 10 (33.3%) | 10.48 ± 1.99 | |
| 3a/3b/3c | 20 (66.7%) | 12.37 ± 1.44 | |
| tPSA | p = 0.868 | ||
| >10 ng/ml | 15 (50.0%) | 11.94 ± 1.87 | |
| <10 ng/ml | 15 (50.0%) | 11.54 ± 1.43 | |
| fPSA/tPSA | p = 0.043 | ||
| <0.16 | 26 (86.7%) | 12.20 ± 1.31 | |
| ≥0.16 | 4 (13.3%) | 8.73 ± 0.92 | |
| Vascular invasion | p = 0.441 | ||
| Present | 4 (13.3%) | 13.45 ± 2.01 | |
| Absent | 26 (86.7%) | 11.48 ± 1.30 | |
| Lymph node metastasis | p = 0.961 | ||
| absent | 28 (93.3%) | 11.73 ± 1.24 | |
| Present | 2 (6.7%) | 11.80 ± 0.50 | |
| Biopsy positive rate | p = 0.067 | ||
| >60% | 5 (16.7%) | 14.26 ± 1.68 | |
| ≤60% | 18 (60.0%) | 9.95 ± 1.18 | |
| N/A | 7 |